Skip to main content

Table 1 Descriptive statistics of all COVID-19 patients included in the study

From: A quantitative analysis of extension and distribution of lung injury in COVID-19: a prospective study based on chest computed tomography

 

All patients

 

Patients without CT

 

Patients with CT

  

Numerosity

111

 

88

 

23

  

Sex (males, %)

82

74

67

78

15

68

 
 

Median

IQR

Median

IQR

Median

IQR

p

Age

61

21

57

20

68

13

0.02*

BMI

29

7

29

6

27

6

0.21

Length of stay in ICU (days)

9

10

7

9

13

15

0.02*

Admission physiology

Median

IQR

Median

IQR

Median

IQR

p

Respiratory rate (breaths/min)

28

13

28

14

28

15

0.61

Heart rate (beats/min)

89

22

88

20

92

25

0.44

Mean arterial pressure (mmHg)

89

18

90

20

86

13

0.31

Body temperature (°C)

38

1

38

1

37.5

0.5

0.86

SAPS3

52

10

51

10

57

13

< 0.01*

Mortality

N

%

N

%

N

%

Dead at 30 days

22

20

14

16

8

36

Premorbidities

N

%

N

%

N

%

Lung disease

28

26

24

28

3

16

Pulmonary hypertension

0

0

0

0

0

0

Smokers (previous or ongoing)

12

24

25

26

8

21

Hypertension

56

52

42

49

12

63

Heart failure

5

5

4

5

1

5

Ischemic heart disease

11

10

7

8

4

21

Vascular disease

19

18

13

15

6

32

Thromboembolic event

10

9

7

8

2

11

Liver failure

1

1

1

1

0

0

Malignant disease

7

6

3

3

3

16

Diabetes

29

27

20

23

7

37

Neurological disease

6

6

6

7

0

0

Psychiatric disease

12

11

11

13

1

5

Preadmission treatment

N

%

N

%

N

%

Steroid treatment

12

11

8

9

3

16

ACEi or ARB

40

37

30

35

9

47

Anticoagulation treatment

24

22

16

19

7

37

  1. Data were reported as median values (IQR) or numerosity (%). Wilcoxon rank sum test to detect statistical differences between patients underwent and patients who did not undergo chest CT (a = 0.05, * to mark statistical significant differences)